Summit Therapeutics, Inc. (NASDAQ:SMMT) Q1 2023 Earnings Conference Call May 11, 2023 9:00 AM ET
Company Participants
Dave Gancarz - SVP, Stakeholder Relations, Business Development & Corporate Strategy
Robert Duggan - CEO & Executive Chairman
Mahkam Zanganeh - Co-CEO, President & Director
Ankur Dhingra - CFO
Urte Gayko - Head, Regulatory Affairs, Quality Assurance & Safety
Conference Call Participants
Operator
Good morning, and welcome to the Summit Therapeutics First Quarter 2023 Earnings and Update Call. [Operator Instructions].
At this time, I would like to introduce the call to Dave Gancarz, Senior Vice President of Stakeholder Relations, Business Development and Corporate Strategy. You may proceed.
Dave Gancarz
Good morning, and thank you for joining us. Our press release was issued earlier this morning and is available on the home page of our website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website www.smmttx.com.
On the call with me today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer; Dr. Maky Zanganeh, our Co-Chief Executive Officer and President; Ankur Dhingra, our Chief Financial Officer as well as Dr. Urte Gayko, our Head of Regulatory, Safety and Quality at Summit.
Before we get started, I would like to note that some statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law. Following comments from Bob, Maky and Ankur, we will take questions.
With that, I will turn the call over to Bob.
Robert Duggan
Thank you, Dave. It's a pleasure to be on the call with each of you this morning. I'm incredibly proud of the accomplishments of Team Summit over the past few months since we closed our transaction with the world-class partners at Akeso. Our relationship discussions with Akeso began in July of 2022 through our business development channels. By October, we had achieved a vision and a concept of what a partnership with Akeso, including their bispecific drug, ivonescimab, could potentially generate under Team Summit's stewardship. Throughout November, we gained additional data and evaluated it properly on not only the company, but the product itself.